In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Aridis Pharmaceuticals (ARDS – Research Report). The company’s shares opened today at $0.76.
According to TipRanks, McCarthy is an analyst with an average return of -33.5% and a 19.14% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Oncolytics Biotech, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Aridis Pharmaceuticals is a Moderate Buy with an average price target of $6.00.
See today’s best-performing stocks on TipRanks >>
ARDS market cap is currently $25.59M and has a P/E ratio of -0.35.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.
Read More on ARDS:
- Aridis Pharmaceuticals price target lowered to $10 from $19 at H.C. Wainwright
- Aridis drops after endpoint in AR-301–002 study not statistically significant
- Aridis: No statistical significance in primary endpoint in AR-301–002 study
- Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
- New Approaches to Treating Infections in Cystic Fibrosis Patients – AR 501 Phase 2 Trial Update
